usp30 inhibitor 11

USP30 inhibitor 11 (USP30-IN-11) is a selective USP30 inhibitor (IC50: 0.01 µΜ) that inhibits SVA and can be used in studies of cancer, mitochondrial dysfunction and Parkinson's.

Prolyl-4-hydroxylase Inhibitor 11, a novel proline 4-hydroxylase inhibitor, shows protective effects against oxidative stress and Cu(II) toxicity in Chlorella vulgaris.

4-(2-fluorophenyl)-2,3-dihydro-1,3-thiazol-2-one is a thiazol-2-one analog that has been found to possess anti-inflammatory, antibacterial, antifungal, and antitumor activities.

gp120-α4β7 binding inhibitor 11 is an anti-HIV agent. gp120-α4β7 binding inhibitor 11 interferes the binding of HIV associated glycoprotein gp12G with the integrin α4β7 (IC50=1.64nM).

USP30 inhibitor 18 is a selective USP30 inhibitor with an IC50 of 0.02 μM. USP30 inhibitor 18 increases protein ubiquitination and accelerates mitophagy[1]. [1]. Arthur F Kluge, et al. Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Bioorg Med Chem Lett. 2018 Aug 15;28(15):2655-2659.

mTOR inhibitor 11 is a useful organic compound for research related to life sciences. The catalog number is T9309 and the CAS number is 1195785-35-3.

δ-secretase inhibitor 11 is an inhibitor of δ-secretase and can be used as a lead compound for translational development of AD treatment.

mTOR inhibitor-11 (Compound 9) is a brain-penetrant compound that inhibits mTOR with an IC50 of 21 nM for pS6 and exhibits inhibitory activity against pCHK1 and PDE4D with IC50 values of 17.2 μM and 17.0 μM, respectively. This compound is utilized in CNS disease research [1].

KRAS inhibitor-11 is a KRAS inhibitor .

HIV-1 inhibitor-11 [a fused pyridine ring derivative] is an HIV-1 inhibitor.

BRD4 Inhibitor-30 (Compound 1) acts as a BRD4 inhibitor, exhibiting an IC50 value of 415 nM [1].

Topoisomerase I inhibitor 11 effectively inhibits Topoisomerase I and has the capability to bind to BTK [1].

HIV-1 inhibitor-30 (compound 10i) is a potent inhibitor of HIV-1, specifically targeting the RT DNA polymerase enzyme, showing strong antiretroviral activity with an EC50 value of 40 nM and an IC50 value of 80 nM. Moreover, it demonstrates significant effectiveness against seven NNRTI-resistant strains of HIV-1 (RT-K103N; RT-Y181C; RT-K103N, Y181C; RT-L100I, K103N; RT-Y188L; RT-K103N, G190A; RT-K103N, V108I), with IC50 values from 0.04 to 1.42 μM. This compound holds potential for AIDS research [1].

ATX inhibitor 11 is a potent inhibitor of ATX (autotaxin) (IC50: 2.7 nM). ATX inhibitor 11 alleviates the severity of fibrotic tissue and effectively reduces the deposition of α-SMA, a biomarker of fibrosis, in a mouse model of fibrosis. ATX inhibitor 11 can be used to study lung fibrosis.

Carbonic anhydrase inhibitor 11 (compound VI) is a potent, selective inhibitor of carbonic anhydrase, targeting CA II (Ki: 40 nM), CA IX (Ki: 39 nM), and CA XII (Ki: 900 nM).

Aurora Kinase Inhibitor-11 (compound 25) acts as an inhibitor against Aurora Kinase, exhibiting a potent IC50 of 0.14 μM. The compound also demonstrates anticancer activity [1].

Compound 14, also known as Tuberculosis Inhibitor 11, enhances the antimycobacterial efficacy of antitubercular agent [1].

FGFR1 inhibitor-11 (compound 5g) effectively targets and binds to FGFR1, subsequently inhibiting the downstream signaling pathways ERK1 2 and IκBα NF-κB, which results in the suppression of RANKL-induced osteoclastogenesis. This compound also exhibits oral bioactivity [1].

KRAS G12D inhibitor 11 is a potent inhibitor of KRAS G12D, a key protein in the Ras family involved in crucial intracellular signaling for growth and development. This inhibitor has shown potential for investigating KRAS G12D-mediated cancers [KRAS G12D, Ras family, intracellular signaling, growth, development, cancer].

KRAS G12C inhibitor 30 is an inhibitor of KRAS G12C and can be used to study cancer.

HIV-1 integrase inhibitor 11 (compound 5) effectively inhibits HIV-1 integrase (HIV-1integrase), with an IC50 of 125 μM.

c-Myc inhibitor 11 (Compound 67e), a c-MYC inhibitor (p EC 50: 6.4), demonstrates high clearance, moderate volume of distribution, and a short half-life in rat pharmacokinetic assays, making it suitable for cancer research [1].

Glutaminase C Inhibitor 11 is a potent inhibitor specifically targeting Glutaminase C (GAC), demonstrating significant inhibition of GAC enzyme activity with an EC50 value of 10.64 nM. It effectively diminishes the viability of A549 non-small cell lung cancer (NSCLC) cells, presenting an IC50 of 4.025 nM. Moreover, at concentrations of 0.1 and 1 µM, it substantially impedes colony formation and reduces intracellular glutamate levels in A549 cells. Demonstrating efficacy in vivo, Glutaminase C Inhibitor 11 at a dosage of 100 mg/kg markedly curtails tumor growth in an A549 mouse xenograft model.

Tubulin Inhibitor 30, exhibiting an IC50 value of 0.52 μM, functions as an inhibitor of tubulin assembly. Additionally, it can induce ferroptosis.

Topoisomerase II inhibitor 11 (compound 3d) is a potent inhibitor of Topoisomerase II (IC50: 2.89 μM), inhibiting cell proliferation and inducing apoptosis by arresting the cell cycle in the G2 M phase.

GSK-3β inhibitor 11 (compound 21) is a potent glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 10.02 μM, demonstrating potential utility in neurodegenerative disease research [1].

Chitin synthase inhibitor 11 is a powerful chitin synthase (CHS) inhibitor that markedly reduces CHS activity (IC50: 0.10 mM) and exhibits broad-spectrum in vitro antifungal activity.

Tubulin Inhibitor 11 is a potent, orally active agent that inhibits tubulin by targeting the Colchicine binding site. It impedes tubulin polymerization, leading to mitotic blockade and apoptosis.